National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1969 No.

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1968.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1968.

Dated this twenty-first day of March, 1969.

CASEY

Governor-General.

By His Excellency's Command,

(SGD.) A. J. FORBES

Minister of State for Health.

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on the first day of April, 1969.

First schedule.

2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after item 38 the following item:—

" 38a. Caffeine Hydrate ";

(b) by inserting after item 130 the following item:—

" 130a. Dusting Powder Absorbable ";

(c) by omitting item 187; and

(d) by inserting after item 266 the following item:—

" 266a. Oil of Coriander ".

Second Schedule.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 3.

Third Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.

Fifth Schedule.

5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.

* Notified in the Commonwealth Gazette on  1969.

  Statutory Rules 1960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote to Statutory Rules 1968, No. 44; and see also Statutory Rules 1968, Nos. 44, 76, 88 and 146.

11928/69—Price 10c  14/11.3.1969

THE SCHEDULES

FIRST SCHEDULE  Regulation 4.

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 2 insert;—

" 2a. Acetylcholine Chloride ".

2. Omit item 19.

3. After item 48 insert:—

" 48a. Betamethasone Valerate ".

4. After item 49 insert:—

" 49a. Black Snake Antivenene ".

5. After item 67 insert:—

" 67a. Capreomycin Sulphate ".

6. After item 70 insert:—

" 70a. Carbenicillin ".

7. After item 91 insert:—

" 91a. Clioquinol

91b. Clofibrate ".

8. After item 116 insert:—

" 116A. Dihydroergotoxine Mesylate ".

9. After item 149a insert:—

" 149b. Flumethasone Pivalate ".

10. Omit from item 157 " Formula No. 11 " insert " Formula No. 17 ".

11. After item 160 insert:—

" 160a. Gentamicin Sulphate ".

12. Omit item 186.

13. After item 231 insert:—

" 231a. Methysergide Malcate ".

14. After item 237 insert: —

" 237a. Nandrolone Hexoxyphenyl Propionate ".

15. After item 251 insert:—

" 251a. Oxethazaine ".

16. Omit item 261.

17. After item 323 insert:—

" 323a. Snake Bite Antivenene —Polyvalent ".

18. After item 331b insert:—

" 331c. Soyalac ".

19. Omit item 365, insert:—

" 365. Tetracosactrin ".

SECOND SCHEDULE  Regulation 5.

Amendments of the Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 1, insert:—_
" 1	Acetylcholine Chloride with Mannitol B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
1a	Acetylcysteine .......................................................	Fibrocystic disease ".

 

Second Schedule—continued

2. Item 22—

(a) omit "Betamethasone Tablets" (in the second column), insert:—

" (1) Betamethasone Syrup

(2) Betamethasone Tablets ";

(b) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(c) insert after " Cushing's syndrome including hyperadrenocorticalism "(in the third column)—

" Dermatitis herpetiformis ";

(d) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis "; and

(e) add at the end of the item (in the third column)—

" With the written authority of the Director-General, for the treatment, in conjunction with other therapy—

(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or

(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn."

3. After item 24 insert:—

" 24a Betamethasone Valerate with Clioquinol For the treatment of diseases of the ear ".

4. After item 29 insert:—

" 29a	Capreomycin Sulphate ................................	Any disease or condition in a patient receiving treatment in or at an approved hospital ".
5. After item 30 insert:—
" 30a	Carbenicillin...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital ".
6. After item 32 insert:—
" 32a	Clofibrate ...................................................	With the written authority of the Director-General, for the treatment of hypercholesterolemia with xanthomata ".

7. Item 46—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(b) insert after " Dermatitis, acute exfoliative " (in the third column)—

" Dermatitis herpetiformis ";

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis ".

8. Add at the end of item 47 (in the third column)—

" With the written authority of the Director-General, for the treatment, in conjunction with other therapy—

(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or

(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn."

9. Item 56—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(b) insert after " Cushing’s syndrome including hyperadrenocorticalism " (in the third column)—

" Dermatitis herpetiformis "; and

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis ".

Second Schedule—continued

10. After item 64 insert:—_
“ 64a	Dihydroergotoxine Mesylate ..............................................	For the treatment of patients who have suffered an attack of paralytic poliomyelitis ".
11. After item 79 insert:—
" 79a	Flumethasone Pivalate and Clioquinol	For the treatment of diseases of the ear ".
12. Omit items 82 and 83, insert:—
" 82	Fluphenazine Oenanthate ..............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
Fluphenazine Oenanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
Huntington's chorea
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
82a	Fluphenazine Hydrochloride ..............................................	Any disease or condition in a pensioner Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:—
Fluphenazine Oenanthate
Fluphenazine Hydrochloride
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
Huntington's chorea
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
83	(1) Folic Acid Injection ..............................................	Macrocytic anaemia
(2) Folic Acid Tablets, B.P..............................................	Sprue or the sprue- like syndrome
Proven folic acid deficiency ".
13. Omit from item 87 " No. 11 " (in the second column), insert " No. 17 ".

Second Schedule—continued

14. After item 88 insert:—_
" 88A	Gentamicin Sulphate .......................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital ".

15. Item 96—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(b) insert after " Cushing's syndrome including hyperadrenocorticalism (in the third column)—

" Dermatitis herpetiformis "; and

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis ".

16. After item 106 insert:—
" 106a	Influenza Vaccine ............................................................	For the treatment of pensioners only ".
17. Omit item 112, insert:—
" 112	Lincomycin Hydrochloride ............................................................	Gram positive coccal infections where these cannot be safely and effectively treated with penicillin
Osteomyelitis ".

18. Item 128—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(b) insert after " Cushing's syndrome including hyperadrenocorticalism " (in the third column)—

" Dermatitis herpetiformis ";

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis "; and

(d) add at the end of the item (in the third column)—

" With the written authority of the Director-General, for the treatment, in conjunction with other therapy—

(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or

(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn ".

19. After item 129 insert:—
" 129a	Methysergide Maleate ..............................	With the written authority of the Director-General, for the treatment of severe recalcitrant migraine where other treatment has failed ".
20. After item 134 insert:—
" 134a	Nandrolone Hexoxyphenyl Propionate	Mammary carcinoma With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long term treatment with corticosteroids ".
21. Omit item 136, insert:—
" 136	Nandrolone Decanoate .............................	Mammary carcinoma With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long term treatment with corticosteroids ".
22. Omit from item 143 " in children " (in the third column).

Second Schedule—continued

23. Item 159—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ",

(b) insert after " Cushing's syndrome including hyperadrenocorticalism " (in the third column)—

" Dermatitis herpetiformis "; and

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis ".

24. Item 173—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(b) insert after " Cushing's syndrome including hyperadrenocorticalism " (in the third column)—

" Dermatitis herpetiformis ";

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis "; and

(d) add at the end of the item (in the third column)—

" With the written authority of the Director-General, for the treatment, in conjunction with other therapy—

(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or

(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn ".

25. Item 178—

(a) insert after " Agranulocytosis " (in the third column)—

" Angioneurotic oedema ";

(b) insert after " Cushing's syndrome including hyperadrenocorticalism " (in the third column)—

" Dermatitis herpetiformis ";

(c) insert after " Reticulum cell sarcoma " (in the third column)—

" Retroperitoneal fibrosis "; and

(d) add at the end of the item (in the third column)—

" With the written authority of the Director-General, for the treatment, in conjunction with other therapy—

(a) of chronic or recurrent asthma in the case of a patient whose asthma interferes seriously with his normal activities of life; or

(b) of a severe asthmatic whose acute attacks of asthma have been relieved by corticosteroids but who relapses when corticosteroids are withdrawn ".

26. Omit from item 181 " Propranolol Hydrochloride " (in the second column), insert—

" (1) Propranolol Hydrochloride, 40 mg. tablets

(2) Propranolol Hydrochloride Injection ".

27. After item 181 insert:—
" 181a	Propranolol Hydrochloride, 10 mg. Tablets	With the written authority of the Director-General, Hypertrophic subaortic stenosis ".
28. Omit item 187, insert:—
" 187	Pyrimethamine Tablets .............................	Treatment of—
Toxoplasmosis
Malaria ".
29. After item 191 insert:—
" 191a	Soyalac ...................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years ".

Second Schedule—continued

30. Omit from item 205 (in the second column) " Tetracosactide ", insert:—

" Tetracosactrin ".

31. Insert in item 210, before " Late-stage malignancy " (in the third column)—

" Huntington's chorea ".

32. Insert in item 216, before " Late-stage malignancy " (in the third column)—

" Huntington's chorea ".

Printed for the Government of the Commonwealth by W. G. Murray at the Government Printing Office. Canberra